Cogenics’s offerings will include biorepository and extraction services in combination with whole genome association and targeted genotyping for Astellas’s clinical studies in the US, Europe and Asia.
Michael Lutz, global manager of Cogenics, said: “We are pleased to partner with Astellas, one of the world’s top pharmaceutical companies, to be their exclusive provider in offering our full spectrum of genotyping services. As life sciences’ research and pharmaceutical development truly becomes a global endeavor, we are well positioned to deliver comprehensive genotyping solutions to our customers worldwide.”